HER2+ BC: A Year in Review and Updates from SABCS

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.

EP. 1: 2020 in Review: HER2+ Breast Cancer

January 29th 2021

Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.

EP. 2: HER2+ BC: Unanswered Questions in Sequencing

January 29th 2021

Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.

EP. 3: Predictive Biomarkers: HER2-Enriched Subtypes

January 29th 2021

Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.

EP. 4: Prognostic Tools for Early Stage BC

January 29th 2021

A discussion on the importance of prognostic tools for early stage breast cancer.

EP. 5: SABCS 2020 Updates: ExteNET and CONTROL Trials

January 29th 2021

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

EP. 6: De-escalation in Neoadjuvant Setting for HER2+ BC

January 29th 2021

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

EP. 7: Disease-Free Interval and Overall Survival in HER2+ BC

January 29th 2021

Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.

EP. 8: Ongoing Role of TDM-1 in Metastatic Breast Cancer

January 29th 2021

Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.

EP. 9: SABCS 2020: PERTAIN Updates in HER2+, HR+ MBC

February 2nd 2021

Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.

EP. 10: Promising Data for Trastuzumab Deruxtecan Combination

February 2nd 2021

Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.